A Prospective Open Pilot Study With Functional Placebo-control to Evaluate the Efficacy and Tolerability/Safety of a Subretinal Implant in Blind Patients in Accordance With ICH/GCP Guidelines
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Retinitis Pigmentosa
- Sponsor
- Retina Implant AG
- Enrollment
- 15
- Locations
- 2
- Primary Endpoint
- Visual Acuity / Light-perception / Object-orientation are significantly improved with implant-ON versus OFF as shown via FrACT / BaLM / grating test (i.e. EFFICACY)
- Status
- Completed
- Last Updated
- 14 years ago
Overview
Brief Summary
The outcome of this trial will reveal the possibilities of the retinal implant to improve the situation of patients with hereditary retinal blindness caused by degenerations of the outer retina. This pilot study will give important information on safety and efficacy of sub-retinal implants.
Detailed Description
Although the design of the chip with a possible resolution of up to 1500 image points has the potential of providing object recognition, the quality of the image transmitted in this first human application cannot be foreseen. On the other hand clinical experience teaches us that even bare light recognition improves mobility of patients because of the ability to localize bright light sources such as windows or lamps.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Hereditary retinal degeneration of the outer retinal layers with the retinal vessels still being perfused and pigments of mild to moderate density
- •Blindness (at least monocular) or visual functions not appropriate for navigation/orientation
- •Period of appropriate visual functions \> 12 years / lifetime
- •Visual acuity ≥ 0,05 in earlier life
- •Electrically Evoked Phosphenes provide evidence of inner-retinal function.
- •willing and able to give written informed consent
Exclusion Criteria
- •Any other ophthalmologic disease with relevant effect upon visual function (e.g. glaucoma, optic neuropathy, trauma, diabetic retinopathy, retinal detachment)
- •Systemic disease that might imply considerable risk with regard to the surgical intervention and anesthesia (e.g. cardiovascular diseases, severe metabolic diseases)
- •Neurological and/or psychiatric diseases (e.g. M. Parkinson, epilepsy, depression )
- •Retina detected as too thin (\< 100 µm) to expect required rest-functionality as shown via Optical Coherence Tomography (OCT).
- •Women who are pregnant or nursing, or women of childbearing potential who are not willing to use a medically acceptable means of birth control for the duration of the study, or women unwilling to perform a pregnancy test before entering the study
- •Participation in another clinical trial within the past 30 days
Outcomes
Primary Outcomes
Visual Acuity / Light-perception / Object-orientation are significantly improved with implant-ON versus OFF as shown via FrACT / BaLM / grating test (i.e. EFFICACY)
Time Frame: within implantation period
Patient treatment shows acceptable results (i.e. SAFETY)
Time Frame: within implantation period
Secondary Outcomes
- Activities of Daily Living are significantly improved with implant-ON versus OFF, as shown via Tasks of Daily Living test / Orientation & Mobility test (i.e. EFFICACY)(within implantation period)
- Non-acceptable surgical complications will terminate clinical study (i.e. SAFETY)(within implantation period)